HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of pharmacological and toxicological methods

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vascn.2010.04.013PMID 20460162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regenerative medicine today

  2013cited by this paper
• The Holy Grail of Hepatocyte Culturing and Therapeutic Use

  2009cited by this paper
• Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes.

  2009cited by this paper
• Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil

  2008cited by this paper
• Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies

  2008cited by this paper
• Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine

  2008cited by this paper
• HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans

  2008cited by this paper
• Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies

  2008cited by this paper
• Effect of voriconazole on the pharmacokinetics of diclofenac

  2007cited by this paper
• The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

  2007cited by this paper
• Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor

  2007cited by this paper
• Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro

  2006cited by this paper
• EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS

  2006cited by this paper
• Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.

  2006cited by this paper
• Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures.

  2005cited by this paper
• EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES

  2005cited by this paper
• Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism

  2003cited by this paper
• Mechanisms of troglitazone hepatotoxicity.

  2003cited by this paper
• An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

  2003cited by this paper
• Effects of troglitazone on HepG2 viability and mitochondrial function.

  2002cited by this paper
• Infection of a human hepatoma cell line by hepatitis B virus

  2002cited by this paper
• Cryopreservation of adult human hepatocytes obtained from resected liver biopsies.

  2002cited by this paper
• Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures.

  2001cited by this paper
• Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2.

  2001cited by this paper
• Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations

  2001cited by this paper
• Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Aldehyde Oxidase‐catalysed Oxidation of Methotrexate in the Liver of Guinea‐pig, Rabbit and Man

  1999cited by this paper
• Induction of cytochrome-P450 in cryopreserved rat and human hepatocytes.

  1999cited by this paper
• Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A

  1998cited by this paper
• Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man.

  1998cited by this paper
• Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.

  1998cited by this paper
• Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes.

  1997cited by this paper
• Expression of the Human Aryl Hydrocarbon Receptor Complex in Yeast

  1997cited by this paper
• The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man.

  1995cited by this paper
• Contribution of amine oxidases to the metabolism of xenobiotics.

  1994cited by this paper
• Use of human hepatocyte cultures for drug metabolism studies.

  1993cited by this paper
• Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.

  1993cited by this paper
• Cytochrome P450: progress and predictions

  1992cited by this paper
• Analysis of plasma protein and lipoprotein synthesis in long-term primary cultures of baboon hepatocytes maintained in serum-free medium

  1989cited by this paper
• Dependence of hepatocyte‐specific gene expression on cell‐cell interactions in primary culture.

  1985cited by this paper
• Isolation, Culture and Characterization of Adult Human Hepatocytes from Surgical Liver Biopsies

  1984cited by this paper
• Cultured human adult hepatocytes: a new model for drug metabolism studies.

  1983cited by this paper

• Surface pattern-embedded microfluidic chip for long-term maintenance of hepatocytes

  2025cites this paper
• A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models

  2025cites this paper
• Alternatives to animal-derived extracellular matrix hydrogels? An explorative study with HepaRG cells in animal-free hydrogels under static and dynamic culture conditions

  2025cites this paper
• Advances in Antituberculosis Drug-induced Liver Injury: Molecular Mechanisms, Genetic Insights, and Emerging Animal-Free Prediction Models.

  2025cites this paper
• Exploring the potential of liver microphysiological systems of varied configurations to model cholestatic chemical effects.

  2025cites this paper
• Advances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling

  2025cites this paper
• Hepatic and Extra-Hepatic Metabolism of Propylene Glycol Ethers in the Context of Central Nervous System Toxicity.

  2025cites this paper
• Transferability and Reproducibility of the HepaRG CometChip Assay

  2025cites this paper
• Hepatic and Renal Toxicity of Gardenia Yellow: Repeated-Dose Assessment and Human Oral Equivalent Dose Prediction via IVIVE.

  2025cites this paper
• Integrating a Microphysiological System and Physiologically Based Pharmacokinetic Modeling to Predict Human Responses to Diclofenac

  2025cites this paper
• Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity.

  2025cites this paper
• Evaluating the synergistic use of advanced liver models and AI for the prediction of drug-induced liver injury

  2025cites this paper
• Cell Painting in HepaRG Cells: An Interlaboratory Reproducibility Study.

  2025cites this paper
• Characterising a HepaRG liver microphysiological system for individual bile acid secretion and chemical induced disruptions.

  2025cites this paper
• In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From β‐Isomer Propylene Glycol Methyl Ether

  2024cites this paper
• Cytotoxic Effects of Major and Emerging Mycotoxins on HepaRG Cells and Transcriptomic Response after Exposure of Spheroids to Enniatins B and B1

  2024cites this paper
• Effects of total saikosaponins on CYP3A4 and CYP1A2 in HepaRG cells

  2024cites this paper
• Application of HepaRG cells for genotoxicity assessment: a review

  2024cites this paper
• Building Metabolically Stable and Potent Anti-HIV Thioether-Lipid Analogues of Tenofovir Exalidex: A thorough Pharmacological Analysis

  2024cites this paper
• In vitro to in vivo extrapolation and high-content imaging for simultaneous characterization of chemically induced liver steatosis and markers of hepatotoxicity

  2023cites this paper
• Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease

  2023cites this paper
• Opportunities and Prospects for Preclinical Drug Safety Assessment Using Alternative Methods: Experience from the Toxicology in the 21st Century (Tox21) Programme in the USA

  2023cites this paper
• General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data

  2023cites this paper
• From vision toward best practices: Evaluating in vitro transcriptomic points of departure for application in risk assessment using a uniform workflow

  2023cites this paper
• Internally crosslinked alginate-based bioinks for the fabrication of in vitro hepatic tissue models

  2023cites this paper
• Unveiling the next generation of bisphenol analogs and their impact on human health using in vitro methods

  2023cites this paper
• Microscale tissue engineering of liver lobule models: advancements and applications

  2023cites this paper
• Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model

  2023cites this paper
• Study of the metabolic stability profiles of perampanel, rufinamide and stiripentol and prediction of drug interactions using HepaRG cells as an in vitro human model.

  2022cites this paper
• Interval-Based Secretomics Unravels Acute-Phase Response in Hepatocyte Model Systems

  2022cites this paper
• Automated Analysis of Acetaminophen Toxicity on 3D HepaRG Cell Culture in Microbioreactor

  2022cites this paper
• Towards better prediction of xenobiotic genotoxicity: CometChip technology coupled with a 3D model of HepaRG human liver cells

  2022cites this paper
• Chemical screening of food-related chemicals for human fatty liver risk: Combining high content imaging of cellular responses with in vitro to in vivo extrapolation

  2022cites this paper
• Towards 3D-bioprinted Models of the Liver to Boost Drug Development.

  2022cites this paper
• Organ-On-A-Chip Technology: An In-depth Review of Recent Advancements and Future of Whole Body-on-chip

  2022cites this paper
• Integration of a microfluidic multicellular coculture array with machine learning analysis to predict adverse cutaneous drug reactions.

  2022cites this paper
• Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells

  2022cites this paper
• Mimicking Native Liver Lobule Microarchitecture In Vitro with Parenchymal and Non-parenchymal Cells Using 3D Bioprinting for Drug Toxicity and Drug Screening Applications.

  2022cites this paper
• State-of-the-art advancements in Liver-on-a-chip (LOC): Integrated biosensors for LOC.

  2022cites this paper
• A microfluidic thyroid-liver platform to assess chemical safety in humans.

  2022cites this paper
• Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models

  2022cites this paper
• In vitro toxicological assessment of PhSeZnCl in human liver cells

  2022cites this paper
• The role of cytochromes CYP1A and CYP3A in the genotoxic effect of benzo(a)pyrene

  2022cites this paper
• Through a glass, darkly? HepaRG and HepG2 cells as models of human phase I drug metabolism

  2022cites this paper
• Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction

  2022cites this paper
• Optimisation of the HepaRG cell line model for drug toxicity studies using two different cultivation conditions: advantages and limitations

  2022cites this paper
• Application and research progress of in vitro liver cancer cell culture models

  2021cites this paper
• Variability in Human In Vitro Enzyme Kinetics.

  2021cites this paper
• ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET].

  2021cites this paper
• Inhibition of phase-1 biotransformation and cytostatic effects of diphenyleneiodonium on hepatoblastoma cell line HepG2 and a CYP3A4-overexpressing HepG2 cell clone

  2021cites this paper
• A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids.

  2021cites this paper
• The use of in vitro methods in assessing human health risks associated with short‐chain perfluoroalkyl and polyfluoroalkyl substances (PFAS)

  2021cites this paper
• A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies

  2021cites this paper
• Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1

  2021cites this paper
• Effective exposure of chemicals in in vitro cell systems: A review of chemical distribution models.

  2021cites this paper
• A Perfusion Bioreactor for Longitudinal Monitoring of Bioengineered Liver Constructs

  2021cites this paper
• High-throughput toxicogenomic screening of chemicals in the environment using metabolically competent hepatic cell cultures

  2021cites this paper
• Micropatterned Coculture with 3T3-J2 Fibroblasts Enhances Hepatic Functions and Drug Screening Utility of HepaRG Cells.

  2021cites this paper
• Human Organoids for Predictive Toxicology Research and Drug Development

  2021cites this paper
• HepG2 as promising cell-based model for biosynthesis of long-term metabolites - exemplified for metandienone.

  2021cites this paper
• A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

  2021influential citation
• Hepatocyte cultures: From collagen gel sandwiches to microfluidic devices with integrated biosensors

  2021cites this paper
• Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip

  2021cites this paper
• Alternative in vitro models for safety and toxicity evaluation of nutraceuticals

  2021cites this paper
• DMSO-free highly differentiated HepaRG spheroids for chronic toxicity, liver functions and genotoxicity studies

  2021cites this paper
• Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation

  2021cites this paper
• Microfabricated and multilayered PLGA structure for the development of co-cultured in vitro liver models

  2020cites this paper
• Repeated dose multi-drug testing using a microfluidic chip-based coculture of human liver and kidney proximal tubules equivalents

  2020cites this paper
• Predicting direct hepatocyte toxicity in humans by combining high-throughput imaging of HepaRG cells and machine learning-based phenotypic profiling

  2020cites this paper
• P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.

  2020cites this paper
• In Vitro and in Silico Liver Models: Current Trends, Challenges and In Vitro and in Silico Liver Models: Current Trends, Challenges and Opportunities Opportunities

  2020cites this paper
• Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells

  2020cites this paper
• In Vitro and in Silico Liver Models: Current Trends, Challenges and In Vitro and in Silico Liver Models: Current Trends, Challenges and Opportunities Opportunities

  2020cites this paper
• Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease

  2020cites this paper
• Impact of iron oxide nanoparticles on xenobiotic metabolism in HepaRG cells

  2020cites this paper
• Imbalance in the antioxidant defence system and pro-genotoxic status induced by high glucose concentrations: in vitro testing in human liver cells.

  2020cites this paper
• Author Correction: Repeated dose multi-drug testing using a microfluidic chip-based coculture of human liver and kidney proximal tubules equivalents

  2020cites this paper
• Exosomal microRNAs Release as a Sensitive Marker for Drug-Induced Liver Injury In Vitro

  2020cites this paper
• Morgan, K. et al. (2020) Oxygen plasma treated substrates and specific nanopattern promote early differentiation and function of HepaRG

  2020cites this paper
• Effects of genetically modified human skin fibroblasts, stably overexpressing hepatocyte growth factor, on hepatic functions of cocultured C3A cells

  2020cites this paper
• Oxygen Plasma Substrate and Specific Nanopattern Promote Early Differentiation of HepaRG Progenitors

  2020cites this paper
• Toxicity of Topically Applied Drugs beyond Skin Irritation: Static Skin Model vs. Two Organs-on-a-Chip.

  2020cites this paper
• Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells

  2020cites this paper
• How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings—A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish Larvae

  2020cites this paper
• Prediction of in vivo genotoxicity of lasiocarpine and riddelliine in rat liver using a combined in vitro-physiologically based kinetic modelling-facilitated reverse dosimetry approach

  2019cites this paper
• EFFECT OF ARYL HYDROCARBON RECEPTOR AGONISTS AND LIPOPOLYSACCHARIDE ON BENZO(A)PYRENE GENOTOXICITY MARKERS

  2019cites this paper
• 3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications

  2019cites this paper
• Evaluation of Strategies to Improve In Vitro Mutagenicity Assessment: Alternative Sources of S9 Exogenous Metabolic Activation and the Development of an In Vitro Assay Based on MutaMouse Primary Hepatocytes

  2019cites this paper
• Cleavable cellulosic sponge for functional hepatic cell culture and retrieval.

  2019cites this paper
• Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model

  2019cites this paper
• Use of an in vitro–in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine

  2019cites this paper
• Human in vitro models of nonalcoholic fatty liver disease

  2019cites this paper
• Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4.

  2019cites this paper
• Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

  2019cites this paper
• Functional Comparison of HepaRG Cells and Primary Human Hepatocytes in Sandwich and Spheroid Culture as Repeated-Exposure Models for Hepatotoxicity

  2019cites this paper
• Novel strategies for risk assessment of pyrrolizidine alkaloids

  2019cites this paper
• Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage.

  2019cites this paper
• Formulating an improved in vitro hepatic model for drug development and toxicity testing

  2019cites this paper
• ВЛИЯНИЕ АГОНИСТОВ АРИЛГИДРОКАРБОНОВОГО РЕЦЕПТОРА И ЛИПОПОЛИСАХАРИДА НА МАРКЕРЫ ГЕНОТОКСИЧЕСКОГО ДЕЙСТВИЯ БЕНЗ(А)ПИРЕНА

  2019cites this paper
• Characterization Of Cytosolic Sulfotransferase Expression And Regulation In Human Liver And Intestine

  2019cites this paper